Lean NAFLD patients often exhibit insulin resistance and dyslipidemia, and these metabolic abnormalities may promote colorectal carcinogenesis through activation of the insulin–IGF signaling pathway [28]. This evidence concerns the gene INS and metabolic syndrome.